Back

Notice of Nexstim Plc’s Half-Yearly Report H1 2017

11 August 2017

Nexstim Plc (NXTMH:HEX, NXTMS:STO) (“Nexstim” or “Company“), a medical technology company developing and marketing pioneering navigated non-invasive brain stimulation systems for both therapeutic and diagnostic applications, will publish its half-yearly report for the six months ended 30 June 2017 on Wednesday 16 August 2017 at approximately 9:00 am Finnish time.

A conference call for media, investors and analysts will take place at 4:00 pm Finnish time on Wednesday 16 August 2017. Martin Jamieson, Chairman and CEO, and Mikko Karvinen, CFO, will present the financial and operational results followed by a Q&A session.

The dial-in numbers for the conference call are:

Finland: +358 (0) 800 914672

Sweden: +46 (0) 20 089 6377

UK: +44 (0) 20 3003 2666

US: + 1 866 966 5335

Standard International: +44 (0) 20 3003 2666

The call Password is Nexstim.

 

Financial statements release for the year ending 31 December 2017 will be published on or about 28 February 2018.

NEXSTIM PLC

Martin Jamieson, Chairman and CEO

Further information is available on the website www.nexstim.com or by telephone:

Nexstim                                                                       +447715163942

Martin Jamieson, Chairman and CEO      moc.m1508699728itsxe1508699728n@nos1508699728eimaj1508699728.nitr1508699728am1508699728

 

UB Securities Oy (Certified Adviser)                   +358 (0)9 2538 0246

Citigate Dewe Rogerson                                      +44 (0)207 2822949

David Dible/Isabelle Andrews/Shabnam Bashir    ku.oc1508699728.rdet1508699728agiti1508699728c@elb1508699728id.di1508699728vad1508699728

About Nexstim Plc

Nexstim is a medical technology company developing and marketing pioneering navigated non-invasive brain stimulation systems for both therapeutic (NBT® system) and diagnostic (NBS system) applications. Nexstim’s NBS system is the only FDA cleared and CE marked system based on navigated Transcranial Magnetic Stimulation (nTMS) for the pre-surgical mapping of the speech and motor cortices of the brain.

Based on the same technology platform, the Company has developed the Navigated Brain Therapy (NBT®) which is CE marked in Europe for the treatment of stroke, major depression and chronic neuropathic pain.

Nexstim recently filed a 510(k) submission with FDA for NBT® system for the treatment of Major Depressive Disorder (MDD). Nexstim looks forward to introducing the NBT® system for this important indication in early 2018. The NBT® system is currently in a supplemental Phase III study, E-FIT trial, which will recruit 60 patients. The trial is expected to complete in Q2 2018, allowing Nexstim to file for FDA clearance. FDA clearance would allow Nexstim to start marketing and selling its NBT® system for stroke rehabilitation in the USA.

Nexstim shares are listed on the Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit www.nexstim.com


Source: Nexstim